论文部分内容阅读
目前已有包括肾素-血管紧张素系统(renin-angiotensin system,RAS)抑制剂在内的治疗糖尿病肾病的最佳方案。RAS抑制剂除能降低血压外,还具有保护肾脏和心血管功能,这部分地归因于其降低白蛋白尿效应。然而,残余白蛋白尿仍然与糖尿病肾病患者的残余高风险相关联,包括2型糖尿病肾病患者的高心肾事件发病率和死亡率。因此需要新的药物来降低残余风险因素而不致增加副反应。选择性内皮素A受体拮抗剂是一类很有前途的药物,已被证明能够降低糖尿病肾病患者的白蛋白尿。然而,这类药物有
There are currently the best regimens for the treatment of diabetic nephropathy, including renin-angiotensin system (RAS) inhibitors. In addition to being able to lower blood pressure, RAS inhibitors also have protective renal and cardiovascular functions, in part due to their reduced albuminuria effects. However, residual albuminuria is still associated with a residual high risk of patients with diabetic nephropathy, including a high incidence of cardiovascular events and mortality in patients with type 2 diabetic nephropathy. Therefore, new drugs are needed to reduce residual risk factors without increasing side effects. Selective endothelin A receptor antagonists are a class of promising drugs that have been shown to reduce albuminuria in patients with diabetic nephropathy. However, there are such drugs